Ownership history in US BANCORP \DE\ · 21 quarters on record
This page tracks every 13F SEC filing in which US BANCORP \DE\ reported a position in AKERO THERAPEUTICS INC (AKRO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 3,664 | +599 | +19.5% | 0.00% | $174K | — |
| 2025 Q2 | ADDED | 3,065 | +1,300 | +73.7% | 0.00% | $164K | — |
| 2025 Q1 | ADDED | 1,765 | +46 | +2.7% | 0.00% | $71K | — |
| 2024 Q4 | ADDED | 1,719 | +8 | +0.5% | 0.00% | $48K | — |
| 2024 Q3 | REDUCED | 1,711 | -50 | -2.8% | 0.00% | $49K | — |
| 2024 Q2 | ADDED | 1,761 | +48 | +2.8% | 0.00% | $41K | — |
| 2024 Q1 | REDUCED | 1,713 | -1,464 | -46.1% | 0.00% | $43K | — |
| 2023 Q4 | ADDED | 3,177 | +907 | +40.0% | 0.00% | $74K | — |
| 2023 Q3 | REDUCED | 2,270 | -1,391 | -38.0% | 0.00% | $115K | — |
| 2023 Q2 | ADDED | 3,661 | +436 | +13.5% | 0.00% | $171K | — |